Cover Image
市場調查報告書

先進藥物輸送·標的型藥物輸送市場分析·預測 2021年:奈米聚合物粒子·微脂體·微胞·奈米乳液·樹狀聚合物·單株抗體

Advanced & Targeted Drug Delivery Market, Segmentation, Analysis & Forecast to 2021 - Nanoparticles, Polymers, Liposomes, Micelles, Nanoemulsions, Dendrimers, Monoclonal Antibodies by Geography, Therapeutic Area and Stakeholder Environment

出版商 Kelly Scientific Publications 商品編碼 346267
出版日期 內容資訊 英文 380 Pages
訂單完成後即時交付
價格
Back to Top
先進藥物輸送·標的型藥物輸送市場分析·預測 2021年:奈米聚合物粒子·微脂體·微胞·奈米乳液·樹狀聚合物·單株抗體 Advanced & Targeted Drug Delivery Market, Segmentation, Analysis & Forecast to 2021 - Nanoparticles, Polymers, Liposomes, Micelles, Nanoemulsions, Dendrimers, Monoclonal Antibodies by Geography, Therapeutic Area and Stakeholder Environment
出版日期: 2016年04月04日 內容資訊: 英文 380 Pages
簡介

全球先進·標的型藥物輸送市場規模,預測將從目前的1,680億美元到擴大到2021年的3,190億美元,以10.4%的年複合成長率 (CAGR) 成長。

本報告提供先進·標的型藥物輸送市場相關調查,提供您市場概要,各技術·地區·治療領域·次市場別市場分析與預測,並提供主要企業簡介等資訊。

第1章 簡介

第2章 標的型藥物輸送:概要

  • 標的型給藥的必要性
  • 標的型藥物輸送的優點及缺點
  • 托曳標的的種類
  • 標的型藥物輸送載體的理想特徵
  • 標的系統所使用的托曳載體

第3章 標的型藥物輸送·奈米醫學:概要

  • 適合標的型給藥的奈米粒子理想的特徵
  • 治療用Nanoconstructs的尺寸
  • 一個以上的法規當局核準之奈米醫學範例
  • 奈米醫學的標的方法
  • 奈米醫學的內在化機制
  • 奈米醫學的未來方向性
  • 奈米醫學方法範例
  • 奈米醫學方法的理由
  • 市售的口服奈米治療藥
  • 市售的非口服給藥治療藥
  • FDA認證的靜脈給藥奈米醫學範例
  • FDA認證的肺給藥奈米醫學範例
  • FDA認證的皮下,肌肉,經皮及眼內給藥的奈米醫學範例
  • 奈米為基礎的醫療設備·診斷實例
  • 活用於奈米醫學配合用的各種奈米載體種類
  • 各領域藥物的奈米粒子的利用
  • 標的藥物輸送奈米系統的區分

第4章 脂質標的型藥物輸送奈米系統

  • 標的型藥物遞輸系統上微脂體的優點及缺點
  • 基於尺寸·結構的微脂體分類
  • 微脂體的尺寸
  • 新世代的微脂體和特徵
  • 傳統微脂體
  • 改良型微脂體
  • 標的型微脂體
  • 脂質載體的技術開發
  • 以脂質載體為下一個焦點的主要企業

第5章 標的型藥物輸送聚合物型載體

  • 刺激應答或智慧聚合物
  • 聚合物型皮膚疾病局部給藥系統
  • 癌症治療的高分子奈米粒子臨床情形
  • 臨床實驗的高分子奈米粒子為基礎的治療
  • 以高分子載體為下一個焦點的主要企業

第6章 標的型藥物輸送高分子奈米微胞/共聚物

  • 微胞的製造所採用的物質及其藥物持續釋出時間
  • 為了達到微胞的持續性釋放之現有手法
  • 高分子奈米微胞的被動標靶
  • 高分子奈米微胞的主動標靶
  • 刺激應答高分子奈米微胞
  • 多功能高分子奈米微胞
  • 正在開發的含藥物高分子奈米微胞為基礎的產品

第7章 樹狀聚合物系的標的型藥物輸送

  • 樹狀聚合物的3D結構
  • 多功能奈米平台的樹狀分子
  • 市售的·後期開發階段的樹狀聚合物
  • 用樹狀聚合物平台被研究的治療部分
  • 熱敏性樹狀聚合物

第8章 標的型藥物輸送無機奈米粒子

  • 以無機奈米粒子為下一個焦點的企業
  • 藥物輸送碳系奈米粒子
  • 富勒烯
  • 奈米載體的氧化石墨烯 (GO)
  • 黃金系奈米粒子 (AuNPs)
  • 藥物輸送二氧化矽奈米粒子
  • 藥物輸送磁粒子

第9章 標的型給藥細胞為基礎系統

  • 以細胞為基礎載體為下一個焦點的企業
  • 藥物輸送的樹突狀細胞 (DC) 所扮演的角色
  • 藥物輸送人工RBC
  • 藥物輸送幹細胞
  • 藥物輸送細菌鬼

第10章 托曳載體的核酸/胜肽

  • 以核酸適體/核酸/胜肽為焦點的企業
  • 藥物輸送胜肽結合
  • DNA/RNA核酸適體
  • DNA Origami(DNA奈米機器人)

第11章 標靶治療,各適應症:概要

  • 標的型癌症治療
  • 單株抗體 (mAbs) 及標的型藥物輸送
  • 標的型藥物輸送的眼內應用
  • 中樞神經系統 (CNS) 疾病標的型藥物輸送
  • 標的型藥物輸送感染疾病應用
  • 標的型藥物輸送心血管應用
  • 肺部疾病標的型藥物輸送
  • 標的型給藥奈米為基礎的藥物的藥用化妝品

第12章 其他標的型藥物輸送技術

  • 眼內植入
  • 藥劑溶出性血管支架 (DES) ·標的型藥物輸送
  • 微晶片:新的埋包含在內可能藥物輸送技術

第13章 市場分析

  • 醫療的奈米粒子的應用
  • 奈米醫學企業的種類
  • 全球奈米醫學企業
  • 全球標的型藥物輸送市場
  • 全球奈米粒子為基礎的標的型藥物遞輸系統市場
  • 眼內藥物輸送市場
  • 全球置入式藥劑溶出性血管支架 (DES) 市場
  • 肺藥物輸送的預測
  • 標的型藥物輸送市場未來預測
  • 新技術系統對目前標的型藥物輸送市場帶來的影響
  • 藥物輸送的未來方向性
  • 現有的標的型給藥市場上顛覆性技術

第14章 主要企業簡介

圖表一覽

目錄
Product Code: 2016TarDDR

This newly published report is a global industry analysis on the advanced and targeted drug delivery market that KellySciPub forecasts to grow at a 10.4% CAGR to $319 billion by 2021 from $168 billion today. Supported by over 300 tables and figures, this 382 page report is an extensive industry analysis specifically written for C-Suite, VP and Higher executives within the Pharma and Biotech space.

The advanced and targeted drug delivery market is segmented and analysed through to 2021 with corresponding CAGR breakdown by:

  • Technology (Nanoparticles, Polymers (micelles, dendrimers etc), Monoclonal antibodies, Gold nanoparticles-based drug delivery and imaging, Drug eluting stents)
  • Geography (Global, USA, Europe, RoW)
  • Therapeutic Area (Pulmonary, Ocular drug delivery, Ocular nano-based drug delivery implants, Drug Eluting Stents,
  • Sub-Market Analysis (details below)

The monoclonal antibody market is further broken down and presented as the top selling mAbs by company, class and revenue through to 2021 with corresponding CAGR values. Specific figures are given in relation to Humira, Remicade, Avastin, Rituxan, Soliris, Herceptin, Kadcyla, Perjeta, Lucentis, Xgeva/Prolia, Stelara and Tysarbi.

The global market for nano-based targeted drug delivery is presented by the following sub-markets liposomes, polymers (micelles, dendrimers etc) and gold nano-particles through to 2021 with corresponding CAGR figures.

The global pulmonary drug delivery market is analysed and presented as metered dose inhalers (MDIs), dry powder inhalers (DPIs) and nebulizers through 2021 with corresponding CAGR data. This market is also divided into the following geographical regions USA, Europe, RoW, Global through 2021 with corresponding CAGR analysis.

Our PhD analysts identify breakthrough R&D papers and patents and delve into disruptive technical platforms that is revolutionising drug delivery systems. Business, financial and market analysis is performed on all data collated to yield robust figures and forecast through 2021 with CAGR values. Together, our scientific and business team provides you with their in depth knowledge, experience and perspective on the targeted drug delivery landscape. Stake holder analysis of key players including innovators, developers and commercial partners is performed and an in depth chapter of 170 companies involved is presented. The analysis includes details of how is breakthrough technology adoption is changing the drug delivery landscape and also how emerging products like hydrogels, PEGylated phospholipid nanocarriers and cyclodextrins are disrupting conventional markets.

Key Questions Answered in this Report:

  • What are the maximum drug release times reported for various nano-based drug carriers?
  • What regulatory agencies are approving specific nanomedicines?
  • How many liposome-based drugs are available in the market?
  • How many stealth liposomes have been granted market approval?
  • How many PEGylated liposomes are used for targeted drug delivery?
  • Who are the leading players in liposome-based drug formulation?
  • What are stimuli-responsive polymers?
  • Who are the market leaders in polymer-based drugs?
  • What dendrimer-based drugs are the commercially available for targeted delivery?
  • What are the applications of inorganic nanoparticles in targeted drug deliver?
  • Which companies are focusing on inorganic nanoparticles for targeted drug delivery?
  • What are the applications of magnetic nanoparticles in drug delivery, diagnostic and imaging?
  • What is the global market value of nanomedicines?
  • What is the global market for nanomedicines by therapeutic areas?
  • What is the global market for monoclonal antibodies by geography?
  • What are the best-selling mAbs?
  • What is the global market for major targeted delivery systems?

Table of Contents

1.0. Introduction

  • 1.1. Executive Summary
  • 1.2. About this Report
  • 1.3. Key Questions Answered in this Report

2.0. Targeted Drug Delivery: An Overview

  • 2.1. The Need for Targeted Delivery
  • 2.2. Advantages and Disadvantages of Targeted Drug Delivery
  • 2.3. Types of Drug Targeting
    • 2.3.1. Active Targeting
    • 2.3.2. Passive Targeting
      • 2.3.2.1. Passively Targeted Therapeutic Preparations
      • 2.3.2.2. Polymeric Nanoparticles (NPs) Developed for Passive Delivery of Drugs
  • 2.4. Ideal Characteristics of Targeted Drug Delivery Carriers
  • 2.5. Drug Carriers used in Targeting Systems

3.0. Targeted Drug Delivery and Nanomedicines: An Overview

  • 3.1. Ideal Characteristics of Nanoparticles suited for Targeted Delivery
  • 3.2. Size of Therapeutic Nanoconstructs
  • 3.3. Examples of Nanomedicines Approved by One or More Regulatory Bodies
    • 3.3.1. Brief Description of Approved Nanomedicines
      • 3.3.1.1. Doxil
      • 3.3.1.2. Myocet
      • 3.3.1.3. DaunoXome
      • 3.3.1.4. ThermoDox
      • 3.3.1.5. Abraxane
      • 3.3.1.6. Rexin-G
      • 3.3.1.7. Oncaspar
      • 3.3.1.8. Resovist
      • 3.3.1.9. Feridex
      • 3.3.1.10. Marquibo
      • 3.3.1.11. Brentuximab Vedotin (Adectris)
      • 3.3.1.12. Trastuzumab Emtansine (Kadcyla)
    • 3.3.2. Therapeutic Nanomedicines in Clinical Trials
  • 3.4. Targeting Approaches of Nanomedicines
    • 3.4.1. Targets of Nanomedicines in the Body
    • 3.4.2. Targeting Ligands
  • 3.5. Mechanism of Internalization of Nanomedicine
  • 3.6. Future Direction of Nanomedicines
  • 3.7. Examples of Nanomedicine Applications
  • 3.8. Rationale for Nanomedicine Approach
  • 3.9. Commercially Available Oral Nanotherapeutics
  • 3.10. Commercially Available Nanotherapeutics for Parenteral Administration
  • 3.11. Examples of FDA-Approved Nanomedicines for Intravenous Route of Administration
  • 3.12. Examples of FDA-Approved Nanomedicines for Pulmonary Route of Administration
  • 3.13. Examples of FDA-Approved Nanomedicines for Subcutaneous, Intramuscular, Transdermal and Ocular Route of Administration
  • 3.14. Examples of Nano-Based Medical Devices and Diagnostics
  • 3.15. Various Types of Nanocarriers Expoited in Formulating Nanomedicines
    • 3.15.1. Types of Nanoparticles
  • 3.16. Use of Nanoparticles in Different Fields of Medicine
    • 3.16.1. Nanosystems for Cancer Treatment
    • 3.16.2. Use of Nanosystems in Tissue Engineering
    • 3.16.3. Use of Nanoparticles (NPs) in Stem Cell Therapy
    • 3.16.4. Use of Nanoparticles in Contrast Agents
  • 3.17. Segmentation of Targeted Drug Delivery Nanosystems

4.0. Lipid-Based Targeted Drug Delivery Nanosystems

  • 4.1. Advantages and Disadvantages of Liposomes as Targeted Drug Delivery Systems
  • 4.2. Classification of Liposomes on the Basis of Size and Composition
    • 4.2.1. Classification of Liposomes on the Basis of Method of Preparation
  • 4.3. Size of Liposomes
  • 4.4. New Generation of Liposomes and their Features
  • 4.5. Conventional Liposomes
    • 4.5.1. Benefits of Drug Loads in Liposomes
    • 4.5.2. Loading Liposomes with Drugs
    • 4.5.3. Intracellular Delivery of Drugs by Liposomes
    • 4.5.4. Liposome-Based Drugs in the Market
    • 4.5.5. Liposome-Based Drugs for Cancer Therapy
    • 4.5.6. Liposomal Drugs in Clinical Trial
  • 4.6. Modified Liposomes
    • 4.6.1. Stealth Liposomes
      • 4.6.1.1. Approved Stealth Liposomes
  • 4.7. Targeted Liposomes
    • 4.7.1. Stimuli-Sensitive Targeted Liposomes
    • 4.7.2. Targeted Liposomal Drugs for Cancer
  • 4.8. Technology Developments in Lipid-Based Carriers
  • 4.9. Key Players Focusing on Lipid-Based Carriers

5.0. Polymer-Based Carriers for Targeted Drug Delivery

  • 5.1. Stimuli-Responsive or Smart Polymers
    • 5.1.1. Temperature-Responsive Polymers
      • 5.1.1.1. Classification of Thermosensitive Polymers
    • 5.1.2. PH-Sensitive Polymers
    • 5.1.3. Bioresponsive Polymers
    • 5.1.4. Field-Responsive Polymers
  • 5.2. Polymer-Based Topical Delivery Systems for Dermatological Diseases
    • 5.2.1. Natural Polymer-Based Topical Delivery Systems
    • 5.2.2. Topical Delivery Systems Based on Synthetic Polymeric Particles
  • 5.3. Clinical Status of Polymeric Nanoparticles in Cancer Treatment
  • 5.4. Polymeric Nanoparticle-Based Therapeutics in Clinical Trials
  • 5.5. Key Players Focusing on Polymer-Based Carriers

6.0. Polymeric Micelle/Co-Polymers for Targeted Drug Delivery

  • 6.1. Substances used to produce Micelle and their Drug Release Duration
  • 6.2. Existing Approaches to Achieve Sustained Release from Micelle
    • 6.2.1. Stimulai-Responsive Micelles
  • 6.3. Passive Targeting of Polymeric Micelle
  • 6.4. Active Targeting of Polymeric Micelle
  • 6.5. Stimuli-Responsive Polymeric Micelles
  • 6.6. Multifunctional Polymeric Micelles
    • 6.6.1. Examples of Multifunctional Drug-Loaded Micelle
    • 6.6.2. Multifunctional Micelles for the Delivery of siRNA
  • 6.7. Drug-Loaded Polymeric Micelle-Based Products in Development

7.0. Dendrimer-Based Targeted Drug Delivery

  • 7.1. Three-Dimensional Structure of Dendrimers
  • 7.2. Dendrions as Multifunctional Nanoplatforms
  • 7.3. Commercially Available and Late-Stage Dendrimers
  • 7.4. Therapeutic Moieties studied using Dendrimer Platform
  • 7.5. Thermosensitive Dendrimers

8.0. Inorganic Nanoparticles for Targeted Drug Delivery

  • 8.1. Companies Focusing on Inorganic Nanoparticles
  • 8.2. Carbon-Based Nanoparticles for Drug Delivery
    • 8.2.1. Carbon Nanotubes (CNTs)
      • 8.2.1.1. Structure of Carbon Nanotubes
      • 8.2.1.2. Artificial Implants from Carbon Nanotubes (CNTs)
      • 8.2.1.3. Detection of Cancer Biomarker by Carbon Nanotubes
      • 8.2.1.4. Drug and Gene Delivery by Carbon Nanotubes
  • 8.3. Fullerenes
    • 8.3.1. Structure of Fullerene
    • 8.3.2. Biomedical Applications of Fullerenes
  • 8.4. Graphine Oxide (GO) as Nanocarriers
    • 8.4.1. GO for Drug Delivery
  • 8.5. Gold-Based Nanoparticles (AuNPs)
    • 8.5.1. Shapes of Gold Nanoparticles
    • 8.5.2. Imaging Applications of Gold Nanoparticles
    • 8.5.3. Drug Delivery Applications of Gold Nanoparticles
    • 8.5.4. Diagnostic Applications of Gold Nanoparticles
  • 8.6. Silica Nanoparticles for Drug Delivery
    • 8.6.1. Types of Silica Nanoparticles
    • 8.6.2. The Process of Synthesis of SNs
    • 8.6.3. Drugs Delivered through Silica Nanoparticles
  • 8.7. Magnetic Particles for Drug Delivery
    • 8.7.1. Companies Focusing on Magnetic Particles
    • 8.7.2. Typical Design of a Magnetic Nanoparticle
    • 8.7.3. Use of Magnetic Nanoparticles
    • 8.7.4. Diagnostic Use
    • 8.7.5. Coating Materials for Magnetic Nanoparticles
    • 8.7.6. Organic Linkers in Magnetic Nanoparticles
    • 8.7.7. Targeted Magnetic Nanoparticles (MNPs) as Cancer Theranostics
    • 8.7.8. Targeting Magnetic Nanoparticles to Tumors (Passive and Active)
    • 8.7.9. Magnetic Nanoparticles as Diagnostics
    • 8.7.10. Magnetic Nanoparticles as Multimodal Imaging Agents
    • 8.7.11. FDA/EMEA Approved Magnetic Nanoparticle-Based Cotrast Agents

9.0. Cell-Based Systems for Targeted Delivery

  • 9.1. Companies Focusing on Cell-Based Carriers
  • 9.2. Role of Dendritic Cells (DCs) in Drug Delivery
  • 9.3. Engineered RBCs for Drug Delvery
    • 9.3.1. Therapeutic Sites and Targets Accessible for RBC-Delivered Drugs
    • 9.3.2. Examples of Therapeutic Enzymes Encapsulated in Carrier RBCs
  • 9.4. Stem Cells for Drug Delivery
  • 9.5. Bacterial Ghosts for Drug Delivery

10.0. Nucleic Acid/Peptide as Drug Carriers

  • 10.1. Companies Focusing on Aptamers/Nucleic Acids/Peptides
  • 10.2. Peptide Conjugates for Drug Delivery
    • 10.2.1. Peptides as Radfionuclide Carriers
    • 10.2.3. Peptide Hormones
    • 10.2.4. Peptide Vaccines
    • 10.2.5. Peptide as Cytotoxic Drug Carrier
    • 10.2.6. Cell-Penetrating Peptides
    • 10.2.7. Peptides Applied in Cancer Diagnostics
    • 10.2.8. Peptides Applied in Treating Cancer
    • 10.2.9. Peptide-Based Vaccines in Clinical Development
  • 10.3. DNA/RNA Aptamers
    • 10.3.1. Clinical Use of Aptamers
  • 10.4. DNA Origami (DNA Nanorobots)

11.0. Targeted Therapies by Indication: An Overview

  • 11.1. Targeted Cancer Therapies
    • 11.1.1. Identification of Targets in Cancer Therapy
    • 11.1.2. Categories and Examples of Tumor Antigens
    • 11.1.3. Development of Targeted Therapies for Cancer
    • 11.1.4. Targeted Cancer Therapies in Late Stage Development
    • 11.1.5. Companies Focusing on Oncology Applications of Targeted Drug Delivery
  • 11.2. Monoclonal Antibodies (mAbs) and Targeted Drug Delivery
    • 11.2.1. Monoclonal Antibodies (mAbs)
      • 11.2.1.1. Naked mAbs
      • 11.2.1.2. Examples of Naked mAbs and their Fuctions
      • 11.2.1.3. Conjugated mAbs
      • 11.2.1.4. Bispecific mAbs
    • 11.2.2. U.S./E.U.-Approved mAbs
    • 11.2.3. mAbs by Indication Area
    • 11.2.4. mAb Biosimilars in Late Stage Development
    • 11.2.5. Biosimilar mAbs in Development
  • 11.3. Ocular Applications of Targeted Drug Delivery
    • 11.3.1. Ocular Applications of Dendrimer Systems
    • 11.3.2. Ocular Applications of Liposomes
    • 11.3.3. Micelles in Ocular Drug Delivery
      • 11.3.3.1. Micelle Systems Investigated for Ocular Drug Delivery
    • 11.3.4. Viral and Non-Viral Vectors for Ocular Gene Delivery
  • 11.4. Targeted Drug Delivery for Central Nervous System (CNS) Disorders
    • 11.4.1. Blood Brain Barrier (BBB)
    • 11.4.2. Drug Delivery Approaches and Drug Molecules for Brain
    • 11.4.3. Examples of Nanoparticles (NPs) used for Delivery of Drugs across BBB
    • 11.4.4. Examples of Clinically-Approved NPs Therapeutics for CNS Disorders
    • 11.4.5. Dendrimers for CNS Drug Delivery
  • 11.5. Infectious Disease Applications for Targeted Drug Delivery
    • 11.5.1. Liposomes for Antimicrobial Drug Delivery
    • 11.5.2. Polymeric Nanoparticles for Antimicrobial Drug Delivery
    • 11.5.3. Solid Lipid Nanoparticles (SLNs) for Antimicrobial Drug Delivery
    • 11.5.4. Dendrimers for Antimicrobial Drug Delivery
  • 11.6. Cardiovascular Applications for Targeted Drug Delivery
    • 11.6.1. Nanoparticles for Advanced Diagnostics and Therapy of Cardiovascular Diseases
    • 11.6.2. Therapeutic and Theranostic Nanoparticles for CVD
    • 11.6.3. In vivo Nanosensors for CVD
  • 11.7. Targeted Drug Delivery for Pulmonary Diseases
    • 11.7.1. Drugs for Inhalation
    • 11.7.2. Polymers for Colloidal Pulmonary Drug Delivery Systems
    • 11.7.3. Nebulizers with Novel Technologies for Pulmonary Drug Delivery
    • 11.7.4. Novel Dry Powder Inhalers (DPIs)
    • 11.7.5. Types of Nanoparticles used to Encapsulate API Molecules
  • 11.8. Cosmeceutical Applications of Nano-Based Drugs for Targeted Delivery

12.0. Other Targeted Drug Delivery Technologies

  • 12.1. Ocular Implants
    • 12.1.1. Ocular Implants under Clinical Development
    • 12.1.2. FDA-Approved Ocular Drug Delivery Implants
    • 12.1.3. Sustained Trans-Scleral Ocular Drug Delivery
  • 12.2. Drug Eluting Stents (DES) and Targeted Drug Delivery
    • 12.2.1. Polymers for Stent Coatings
  • 12.3. Microchips: The Novel Implantable Drug Delivery Technology

13.0. Market Analysis to 2021

  • 13.1. Applications of Nanoparticles in Healthcare
  • 13.2. Types of Nanomedicine Companies
  • 13.3. Global Market for Nanomedicines to 2021
    • 13.3.1. Nanomedicines Market by Major Therapeutic Area
  • 13.4. Global Market for Targeted Drug Delivery to 2021
    • 13.4.1. Global Market for mAbs to 2021
      • 13.4.1.1. Best-Selling mAbs 2014-2021
      • 13.4.1.2. Global Market for Humira, Remicade and Avastin
      • 13.4.1.3. Global Market for Rituxan, Soliris and Herceptin
      • 13.4.1.4. Global Market for Kadcyla, Perjeta and Lucentis
      • 13.4.1.5. Global Market for Xgeva/Prolia, Stelara and Tysarbi
  • 13.5. Global Market for Nanoparticle-Based Targeted Drug Delivery Systems to 2021
  • 13.6. Ocular Drug Delivery Market to 2021
    • 13.6.1. Novel Ocular Drug Delivery Systems
  • 13.6.1.2. Ocular Drug Delivery Implants
  • 13.7. Global Market for Implanted Drug Eluting Stents to 2021
  • 13.8. Pulmonary Drug Delivery to 2021
  • 13.9. What does the Future hold for the Targeted Drug Delivery Market?
  • 13.10. Impact of New Technology Systems on the Current Targeted Delivery Market
  • 13.11. Future Directions in Drug Delivery
  • 13.12. Disruptive Technologies within the Existing Targeted Delivery Market
    • 13.12.1. Emergence of Hydrogels in Oral Drug Delivery
    • 13.12.2. Emergence of PEGylated Phospholipid Nanocarriers for Respiratory Diseases
    • 13.12.3. Emergence of Cyclodextrins
      • 13.12.3.1. Cyclodextrins in Oral Drug Delivery
      • 13.12.3.2. Cyclodextrins in Rectal Drug Delivery
      • 13.12.3.3. Cyclodextrin in Nasal Drug Delivery
      • 13.12.3.4. Cyclodextrins in Transdermal Drug Delivery
      • 13.12.3.5. Cyclodextrins in Ocular Drug Delivery
      • 13.12.3.6. Cyclodextrins in Controlled Drug Delivery

14.0. Selected Company Profiles

  • 14.1. 3M Company
    • 14.1.1. 3M Drug Delivery Systems
  • 14.2. Abbott Laboratories
    • 14.2.1. Gengraf
    • 14.2.2. Kaletra
    • 14.2.3. Norvir
  • 14.3. Ablynx NV
    • 14.3.1. Nanobody Technology
    • 14.3.2. Clinical Programs
    • 14.3.3. Ablynx's Partnership with Boehringer Ingelheim
    • 14.3.4. Ablynx's Partnership with Eddingpharm
    • 14.3.5. Ablynx's Partnership with Genzyme
    • 14.3.6. Ablynx's Partnership with Merck & Co.
    • 14.3.7. Ablynx's Partnership with Merck KGaA
    • 14.3.8. Ablynx's Partnership with Novartis
    • 14.3.9. Ablynx's Partnership with Taisho Pharmaceutical
  • 14.4. Aciont Inc.
    • 14.4.1. Visulex Technology
  • 14.5. Acrux
    • 14.5.1. Patchless Patch
    • 14.5.2. Axiron
    • 14.5.3. Evamist & Lenzetto
  • 14.6. Agilis Biotherapeutics LLC
    • 14.6.1. Agilis' Engineered DNA Therapeutics
    • 14.6.2. Agilis' DNA Therapeutic Programs
      • 14.6.2.1. DNA Therapeutics for Friedreich's Ataxia
      • 14.6.2.2. DNA Therapeutics for Angelman Syndrome (AS)
  • 14.7. Aileron Therapeutics Inc.
    • 14.7.1. P53 Pathway Re-Activator
  • 14.8. Alchemia Oncology Pty Ltd.
    • 14.8.1. HA-Irinotecan
    • 14.8.2. HA-Doxorubicin (Hyaluronic acid + Doxorubicin)
    • 14.8.3. HA-5-Fluorouracil (Hyaluronic acid + 5-Fluorouracil)
    • 14.8.4. Monoclonal Antibodies
  • 14.9. Alkermes Pharma Ireland Ltd.
    • 14.9.1. Aristada
    • 14.9.2. Vivitrol
    • 14.9.3. U.S. Products using Alkermes' Technologies
      • 14.9.3.1. Bydureon
      • 14.9.3.2. Ampyra
      • 14.9.3.3. Risperdal Consta
      • 14.9.3.4. Invega Trinza
    • 14.9.4. Alkermes' Long-Acting Technologies
      • 14.9.4.1. Medisorb Technology
      • 14.9.4.2. LinkeRx Technology
      • 14.9.4.3. NanoCrystal Technology
  • 14.10. Allergan Inc.
    • 14.10.1. Doryx (Delayed-Release Tablets)
    • 14.10.2. Saphris (Sub-Lingual Tablets)
    • 14.10.3. Namenda XR (Extended Release Capsules)
    • 14.10.4. Namzaric (Extended Release Capsule)
    • 14.10.5. Asacol HD (Delayed-Release Tablets)
    • 14.10.6. Delzicol (Delayed-Release Tablets)
    • 14.10.7. Zenpep (Delayed-Release Tablets)
  • 14.11. Alnylam Pharmaceuticals
    • 14.11.1. Development Pipeline
    • 14.11.2. Strategic Alliances
  • 14.12. AmpliPhi Biosciences
    • 14.12.1. Product Pipeline
  • 14.13. Andros Pharmaceuticals Co., Ltd.
    • 14.13.1. High-End Cosmetic Ingredient
    • 14.13.2. Topical Drug Delivery System
    • 14.13.3. Gene Delivery System
  • 14.14. Angiochem Inc.
    • 14.14.1. LRP-1 Technology
  • 14.15. Antares Pharma Inc.
    • 14.15.1. VIBEX
    • 14.15.2. Pen Injectors
    • 14.15.3. Partnered Products
  • 14.16. Aposense Ltd.
    • 14.16.1. Apo-si
    • 14.16.2. ATT-11T
    • 14.16.3. F-ML-10
    • 14.16.4. ATT-LD
  • 14.17. Applied Genetic Technologies Corp. (AGTC)
    • 14.17.6. Technology
  • 14.18. Aptagen LLC
    • 14.18.1. Apta-Services (R&D Support)
    • 14.18.2. Apta-Index
  • 14.19. Aradigm Corp.
    • 14.19.1. Technology
    • 14.19.2. Aradigm's Product Pipeline
  • 14.20. ArisGen SA
    • 14.20.1. ArisCrown Technology
    • 14.20.2. Sublingual Exenatide ARG011
  • 14.21. Armagen Technologies Inc.
    • 14.21.1. Armagen's Technology
    • 14.21.2. Armagen's Licensing and Collaboration Agreement with Shire
    • 14.21.3. Armagen's Partnership with PacificGMP
  • 14.22. Arrowhead Research Corp.
    • 14.22.1. Arrowhead's Lead Products
    • 14.22.2. The Dynamic Polyconjugate Platform
  • 14.23. Artificial Cell Technologies Inc.
    • 14.23.1. Technology
    • 14.23.2. Respiratory Syncytial Virus (RSV) Vaccine
    • 14.23.3. Malaria Vaccine
  • 14.24. AsclepiX Therapeutics LLC
    • 14.24.1. Anti-Angiogenesis Therapy
  • 14.25. Asklepios BioPharmaceutical Inc.
    • 14.25.1. Asklepios' Collaboration with Baxter
    • 14.25.2. Asklepios' Collaboration with Medtronic
    • 14.25.3. Asklepios' Collaboration with ALS Therapy Development Institute
    • 14.25.4. Asklepios' Collaboration with Genzyme
    • 14.25.5. Asklepios' Collaboration with Pfizer
  • 14.26. Astellas Pharma Inc.
    • 14.26.1. AmBisome
  • 14.27. Audentes Therapeutics Inc.
    • 14.27.1. Technology
  • 14.28. Avalanche Biotechnologies Inc.
    • 14.28.1. The Ocular BioFactory Platform
  • 14.29. Avita Medical Ltd.
    • 14.29.1. ReCell FOR Burns and Plastics
    • 14.29.2. ReCell for pigmentation
    • 14.29.3. ReCell for Chronic Wounds
    • 14.29.4. Funhaler
    • 14.29.5. Breath-A-Tech
  • 14.30. Azaya Therapeutics Inc.
    • 14.30.1. Products
  • 14.31. Bachem Americas Inc.
    • 14.31.1. API Products
  • 14.32. Bayer Pharma AG
    • 14.32,1. Cipro
  • 14.33. BBB Therapeutics BV
    • 14.33.1. G-Technology
    • 14.33.2. Product Pipeline
  • 14.34. Bespak Europe Ltd.
    • 14.34.1. Inhalation Delivery Devices
    • 14.34.2. Injectable Drug Delivery Devices
    • 14.34.3. VapourSoft Technology
    • 14.34.4. ASI Technology
  • 14.35. Bicycle Therapeutics Ltd.
    • 14.35.1. Bicycle Molecules
    • 14.35.2. R & D in Oncology
    • 14.35.3. R & D in Ophthalmology
  • 14.36. BigDNA Ltd.
    • 14.36.1. Technology
  • 14.37. BIND Therapeutics Inc.
    • 14.37.1. Accurins
    • 14.37.2. BIND Therapeutics' Intellectual Property
    • 14.37.3. BIND's Collaboration with Pfizer
    • 14.37.4. BIND's Collaboration with Merck
  • 14.38. BioDelivery Sciences International Inc.
    • 14.38.1. BEMA Technology
    • 14.38.2. Onsolis
    • 14.38.3. Belbuca (Buprenorphine HCL Buccal Film)
    • 14.38.4. Bunavail
    • 14.38.5. Clonidine Topical Gel
  • 14.39. Bioject Medical Technologies Inc.
    • 14.39.1. Technology
    • 14.39.2. Biojector 2000
    • 14.39.3. Bioject Zetajet
    • 14.39.4. Biojet Drug Reconstitution System
    • 14.39.5. Needle-Free Vial Adapter
  • 14.40. BioZone Laboratories Inc.
    • 14.40.1. QuSomes Technology
    • 14.40.2. LipoSpray Technology
    • 14.40.3. Ela-Max
  • 14.41. Camurus AB
    • 14.41.1. Technologies
      • 14.41.1.1. FluidCrystal Injection Depot
      • 14.41.1.2. FluidCrystal Topical Bioadhesive
      • 14.41.1.3. FluidCrystal Nanoparticles
      • 14.41.1.4. CAM2029
      • 14.41.1.5. CAM2038
      • 14.41.1.6. CAM2038 (Chronic Pain)
      • 14.41.1.7. CAM2032
      • 14.41.1.8. Episil Oral Liquid
  • 14.42. Celsion Corp.
    • 14.42.1. Celsion's LTLD Technology
    • 14.42.2. Celsion's Pipeline
  • 14.43. CeramiSphere Pty Ltd.
    • 14.43.1. Technology
      • 14.43.1.1. Mucosal Delivery of Proteins
      • 14.43.1.2. Delivery of DNA and RNA
      • 14.43.1.3. Delivery of Wound Healing Drugs
  • 14.44. Cerulean Pharma Inc.
    • 14.44.1. Nanoparticle-Drug Conjugates (NDCs)
  • 14.45. Chrysalis BioTherapeutics Inc.
    • 14.45.1. Radiation Therapy (TP508)
    • 14.45.2. Solution for Nuclear Emergencies
    • 14.45.3. Solution for Cardiovascular Disease
    • 14.45.4. Solution for Regenerative Medicine
  • 14.46. Copernicus Therapeutics Inc.
    • 14.46.1. Technology
  • 14.47. Cornerstone Pharmaceuticals Inc.
    • 14.47.1. AEMD Platform
    • 14.47.2. Emulsiphan Pipeline
  • 14.48. CureVac AG
    • 14.48.1. CureVac's RNA Technology Platforms
  • 14.49. CytImmune Sciences Inc.
    • 14.49.1. Aurimune
    • 14.49.2. CYT-6091
    • 14.49.3. CYT-21000
    • 14.49.4. Partnership with Coldstream Laboratories Inc.
  • 14.50. DepoMed Inc.
    • 14.50.1. Acuform Technology
    • 14.50.2. Products
      • 14.50.2.1. Nucynta ER
      • 14.50.2.2. Cambia
      • 14.50.2.3. Lazanda
      • 14.50.2.4. Zipsor
  • 14.51. Dicerna Pharmaceuticals
    • 14.51.1. DsiRNA-EX-Conjugate technology
    • 14.51.2. EnCore Lipid Nanoparticles
  • 14.52. Dimension Therapeutics Inc.
    • 14.52.1. Engineered AAV Vectors
    • 14.52.2. Hemophilia Program
    • 14.52.3. Ornithine transcarbamylase (OTC) deficiency
    • 14.52.4. Glycogen Storage Disease Type Ia (GSDIa)
  • 14.53. Dipexium Pharmaceuticals Inc.
    • 14.53.1. Locilex
  • 14.54. Discovery Laboratories Inc.
    • 14.54.1. AEROSURF - Aerosolized KL4 Sulfactant
    • 14.54.2. KL4 Sulfactant
    • 14.54.3. Capillary Aerosol Generator (CAG) Technology
  • 14.55. DURECT
    • 14.55.1. Technologies
      • 14.55.1.1. Epigenomic Regulator Program
      • 14.55.1.2. Long-Acting Injectables
      • 14.55.1.3. Abuse Deterrant Technology
      • 14.55.1.4. Transdermal Technology
    • 14.55.2. Patents
    • 14.55.3. Products in Development
      • 14.55.3.1. DUR-928
      • 14.55.3.2. POSIMIR
      • 14.55.3.3. REMOXY
      • 14.55.3.4. ORADUR
      • 14.55.3.5. ORADUR - Methylphenidate
      • 14.55.3.6. RELDAY
      • 14.55.3.7. ELADUR
    • 14.55.4. Commercial Products
      • 14.55.4.1. ALZET Osmotic Pumps
      • 14.55.4.2. LACTEL
  • 14.56. EnGeneIC Ltd
    • 14.56.1. EDV Nanocells
    • 14.56.2. Completion of Series B Financing
    • 14.56.3. 2015 Thomson Reuters Award
    • 14.56.4. EnGeneIC's Phase I Clinical Study for Advanced Glioma Patients
  • 14.57. Ensysce Biosciences Inc.
    • 14.57.1. Single-Walled Carbon Nanotubes (SWCNT)
    • 14.57.2. Ensysce's Product Pipeline
  • 14.58. EryDel SpA
    • 14.58.1. Technology
    • 14.58.2. EryDex System
  • 14.59. EryTech Pharma
    • 14.59.4. ERY-ASP (GRASPA)
    • 14.59.5. EryTech's Key Corporate Facts
    • 14.59.6. Deloitte Award
  • 14.60. Esperance Pharmaceuticals Inc.
    • 14.60.1. MDPs Technology
    • 14.60.2. Pipeline
  • 14.61. Exicure Inc.
    • 14.61.1. SNA Platform
  • 14.62. FIT Biotech Oy
    • 14.62.1. Gene Transfer Unit (GTU) Platform
  • 14.63. Flamel Technologies S.A.
    • 14.63.1. Flamel's Drug Delivery Platforms
    • 14.63.2. Micropump
    • 14.63.3. LiquiTime
    • 14.63.4. Trigger Lock
    • 14.63.5. Medusa
  • 14.64. Generex Biotechnology Corp.
    • 14.64.1. RapidMist Technology
    • 14.64.2. Antigen Express Technology
    • 14.64.3. Generex Oral-Lyn
  • 14.65. Genetic Immunity Inc.
    • 14.65.1. DermaVir
    • 14.65.2. Technology
      • 14.64.2.1. DermaPrep
      • 14.64.2.2. ANTIGENeering
      • 14.64.2.3. Nanomedicine
  • 14.65. Genus Pharmaceuticals Ltd.
    • 14.65.1. Fenogal
  • 14.66. GenVec Inc.
    • 14.66.1. AdenoVerse Technology
  • 14.67. GlaxoSmithKline LLC
    • 14.67.1. Adavir Diskus
    • 14.67.2. Sustiva
    • 14.67.3. Agenerase
  • 14.68. Glide Pharmaceutical Technologies Ltd.
    • 14.68.1. Technologies
  • 14.69. Heron Therapeutics Inc.
    • 14.69.1. Biochronomer Technology
    • 14.69.2. Sustol
    • 14.69.3. HTX-019
    • 14.69.4. HTX-011
  • 14.70. Hoffmann-LaRoche Inc.
    • 14.70.1. Fortovase
  • 14.71. ICB International Inc.
    • 14.71.1. Platform Technology
  • 14.72. iCeutica Inc.
    • 14.72.1. Product Pipeline
    • 14.72.2. SoluMatrix Technology
  • 14.73. ImmusanT Inc.
  • 14.74. InDex Pharmaceuticals AB
    • 14.74.1. Kappaproct
  • 14.75. Immune Design
  • 14.76. Immunocore Ltd.
    • 14.76.1. ImmTACs
  • 14.77. Inovio Pharmaceuticals
    • 14.77.1. SynCon Technology
  • 14.78. Insite Vision Inc.
    • 14.78.1. DuraSite Technology
  • 14.79. Insmed Inc.
  • 14.80. Intezyne Technologies Inc.
    • 14.80.1. IVECT Method
    • 14.80.2. Intezyne's Pipeline
  • 14.81. Keystone Nano Inc.
    • 14.81.1. NanoJacket Technology
    • 14.81.2. NanoLiposome Technology
  • 14.82. Kowa Pharmaceuticals America Inc.
    • 14.82.1. Livalo
    • 14.82.2. Lipofan
  • 14.83. LipimetiX Inc.
    • 14.83.1. Technology
  • 14.84. LiPlasome Pharma ApS
    • 14.84.1. LiPlasome's Pipeline
    • 14.84.2. LiPlaCis
  • 14.85. Lipocine Inc.
    • 14.85.1. LCPN 1021
    • 14.85.2. LCPN 1111
    • 14.85.3. LPCN 1107
    • 14.85.4. Lip'ral Technology
  • 14.86. Lipotek Pty Ltd.
    • 14.86.1. Technology
  • 14.87. Living Cell Technologies Ltd.
    • 14.87.1. DIABECELL
    • 14.87.2. NTCELL
  • 14.88. Madison Vaccines Inc.
    • 14.88.1. Technology
  • 14.89. MagForce AG
    • 14.89.1. NanoTherm Therapy
    • 14.89.2. NanoTherm
    • 14.89.3. NanoPlan
    • 14.89.4. NanoActivator
  • 14.90. Mankind Pharma Ltd.
    • 14.90.1. Technosphere Technology
  • 14.91. Mersana Therapeutics Inc.
    • 14.91.1. Fleximer Platform
    • 14.91.2. Dolaflexin
    • 14.91.3. Mersana's Partnership with Takeda
    • 14.91.4. Mersana's Partnership with EMD Serono
    • 14.91.5. Mersana's Partnership with Recepta Biopharma S.A.
  • 14.92. Micochips Biotech Inc.
    • 14.92.1. Technology
    • 14.92.2. Applications
    • 14.92.3. Current Partnerships
      • 14.92.3.1. Teva Pharmaceuticals
      • 14.92.3.2. Gates Foundation
  • 14.93. Milo Biotechnology LLC
    • 14.93.1. Technology
  • 14.94. miRagen Therapeutics Inc.
  • 14.95. Mirna Therapeutics Inc.
    • 14.95.1. Technology
    • 14.95.2. MRX34
  • 14.96. Miros Polymers Inc.
    • 14.96.1. Technology
    • 14.96.2. Drug Delivery Systems
      • 14.96.2.1. ExCell
      • 14.96.2.2. PolyGel
  • 14.97. Moderna Therapeutics Inc.
    • 14.97.1. mRNA Expression Platform
  • 14.98. MultiVir Inc.
    • 14.98.1. MultiVir's Product Candidates
  • 14.99. Mystic Pharmaceuticals Inc.
    • 14.99.1. VersiDoser Delivery Platform
    • 14.99.2. VRx2 Delivery Platform
    • 14.99.3. Intranasal Delivery Systems
    • 14.99.4. Nose to Brain Delivery Systems
    • 14.99.5. Ophthalmic Delivery Systems
    • 14.99.6. Sublingual Delivery Systems
  • 14.100. Nanobiotix
    • 14.100.1. NanoXray
  • 14.101. Nanocarrier Co., Ltd.
    • 14.101.1. Micellar Nanoparticles
  • 14.102. Nanocopoeia Inc.
    • 14.102.1. ElectroNanospray (ENS) Process
  • 14.103. NanoMedical Systems Inc.
    • 14.103.1. Personalized Molecular Drug Delivery System (PMDS)
    • 14.103.2. NanoMedical Diagnostics (NMD)
    • 14.103.3. Multi-Stage NanoVector Drug Delivery System (MSV)
  • 14.104. NanoOncology Inc. (PeptiMed Inc.)
    • 14.104.1. NanoOncology's Product Pipeline
    • 14.104.2. Ovarian Cancer Program
    • 14.104.3. Breast Cancer Program
    • 14.104.4. Lung Cancer Program
  • 14.105. Nanospectra Biosciences Inc.
    • 14.105.1. AuroLase Therapy
  • 14.106. Nano Precision Medical Inc.
    • 14.106.1. The NanoPortal Solution
  • 14.107. Nanotherapeutics Inc.
  • 14.108. nanoTherics Ltd
    • 14.108.1. magneTherm
    • 14.108.2. Live Cell Alternating Magnetic Field Exposure System (LC-AMF System)
    • 14.108.3. Magnefect System
  • 14.109. NanoVector Inc.
    • 14.109.1. Product Strategy
    • 14.109.2. NVI-9010
  • 14.110. NanoViricides Inc.
    • 14.110.1. Platform Technology
  • 14.111. Nektar Therapeutics
    • 14.111.1. Technology
  • 14.112. Neos Therapeutics Inc.
    • 14.112.1. Proprietary Technology
    • 14.112.2. Rapidly Disintegrating Ionic Masking
    • 14.112.3. Dynamic Time Release Suspension
    • 14.112.4. Kinetically Controlled Tamper Protection
    • 14.112.5. Currently Marketed Product
  • 14.113. NeXstar Pharmaceuticals Inc.
    • 14.113.1. DaunoXome
  • 14.114. NightstaRx Ltd.
    • 14.114.1. AAV2-REP1
  • 14.115. NOD Pharmaceuticals Inc.
    • 14.115.1. Technology
      • 14.115.1.1. Nodlin
      • 14.115.1.2. Nodexen
  • 14.116. Nordic Nanovector ASA
    • 14.116.1. Antibody-Radionucleotide-Cojugate
    • 14.116.2. Betalutin
  • 14.117. Novagali Pharma S.A.
    • 14.117.1. Novasorb Technology
  • 14.118. Novartis Pharmaceuticals Corp.
    • 14.118.1. Neoral
  • 14.119. Ocular Therapeutix Inc.
    • 14.119.1. ReSure Sealant
    • 14.119.2. Dextenza
    • 14.119.3. Sustained Release Travoprost
    • 14.119.4. Posterior Segment Injections
  • 14.120. Oncolytics Biotech Inc.
    • 14.120.1. Reolysin
  • 14.121. Oxford Biomedica plc
    • 14.121.1. OXB-201 (RetinoStat)
    • 14.121.2. SAR 422459
    • 14.121.3. SAR 421869
    • 14.121.4. EncorStat
    • 14.121.5. OXB-102
    • 14.121.6. MoNuDin
    • 14.121.7. OXB-301 (TroVax)
    • 14.121.8. Anti-5T4 Antibody
    • 14.121.9. The LentiVector Platform
    • 14.121.10. 5T4 Tumor Antigen
    • 14.121.11. CAR-T Cell Therapy
  • 14.122. PDS Biotechnology Corp.
    • 14.122.1. Versamune NanoPlatform-
  • 14.123. PharmaIN Corp.
    • 14.123.1. Protected Graft Copolymer (PGC)
  • 14.124. PhaseRx Inc.
    • 14.124.1. mRNA Technology
  • 14.125. Phico Therapeutics Ltd.
    • 14.125.1. Technology
    • 14.125.2. Products
      • 14.125.2.1. SASPject PT1.2
      • 14.125.2.2. SASPject PT3.1
      • 14.125.2.3. SASPject PT4
  • 14.126. PolyActiva Pty Ltd.
    • 14.126.1. Drug Delivery Platform
    • 14.126.2. Glaucoma Program
    • 14.126.3. Endophthalmitis
    • 14.126.4. Osteoarthritis Program
  • 14.127. PolyMicrospheres
  • 14.128. PolyTherics Ltd.
    • 14.128.1. ThioBridge
    • 14.128.2. TheraPEG
    • 14.128.3. HiPEG
    • 14.128.4. CyPEG
    • 14.128.5. PolyPEG
  • 14.129. Presage Biosciences Inc.
    • 14.129.1. CIVO Platform
  • 14.130. pSivida Corp.
    • 14.130.1. Durasert Technology
    • 14.130.2. pSivida's Product Pipeline
    • 14.130.3. Iluvien
    • 14.130.4. Retisert
    • 14.130.5. Durasert/Latanoprost
  • 14.131. Pulmatrix Inc.
    • 14.131.1. iSPERSE
    • 14.131.2. PUR1900
    • 14.131.3. PUR1500
    • 14.131.4. PUR0200
  • 14.132. Quark Pharmaceuticals Inc.
    • 14.132.1. Quark's siRNA Technology Platform
  • 14.133. Ra Pharmaceuticals Inc.
    • 14.133.1. RA101495
    • 13.133.2. Factor D Inhibitor
  • 14.134. RaNA Therapeutics Inc.
  • 14.135. RegeneRx Biopharmaceuticals Inc.
    • 14.135.1. Tβ4 Peptide Research
  • 14.136. Regenxbio Inc.
    • 14.136.1. NAV Technology
  • 14.137. Renova Therapeutics Inc.
  • 14.138. Replicor Inc.
    • 14.138.1. NAP Technology
    • 14.138.2. Replicor's Pipeline
      • 14.138.2.1. Phase II Proof of Concept Clinical Study Pipeline
    • 14.138.3. Replicor's Regulatory Pipeline
  • 14.139. RetroSense Therapeutics LLC
    • 14.139.1. RST-001
  • 14.140. Rexahn Pharmaceuticals Inc.
    • 14.140.1. Supinoxin (RX-5902)
    • 14.140.2. RX-3117
    • 14.140.3. Archexin
    • 14.140.4. RX-21101
    • 14.140.5. Archexin-Nano
  • 14.141. RJS Biologics LLC
    • 14.141.1. Technology
  • 14.142. Roche Holding AG
    • 14.142.1. Rocaltrol
  • 14.142.2. Accutane
    • 14.143. Sarfez Pharmaceuticals Inc.
  • 14.144. Savara Inc.
  • 14.145. Scintipharma Inc.
    • 14.145.1. InteliSite Companion Capsule
  • 14.146. Sequus Pharmaceuticals Inc.
    • 14.146.1. Amphocil
    • 14.146.2. Doxil
  • 14.147. Serina Therapeutics Inc.
    • 14.147.1. POZ Technology
    • 14.147.2. Serina's Pipeline
  • 14.148. Serpin Pharma LLC
    • 14.148.1. SP16
  • 14.149. Silence Therapeutics PLC
  • 14.150. Silenseed Ltd.
    • 14.150.1. The LODER Platform
  • 14.151. Sylentis SA
    • 14.151.1. Bamosiran
    • 14.151.2. SYL 1001
  • 14.152. SoluBest Ltd.
    • 14.152.1. Solumer Technology
    • 14.152.2. Sepomer Technology
    • 14.152.3. Contromer
    • 14.152.4. Advanced Stage Products
    • 14.152.5. Fenofibrate
    • 14.152.6. Albendazole
    • 14.152.7. Resveratrol
    • 14.152.8. Testosterone undecanoate
  • 14.153. Spark Therapeutics
  • 14.154. Spheringenics Inc.
    • 14.154.1. Technology
  • 14.155. Suda Ltd.
    • 14.155.1. Technology
    • 14.155.2. ZolpiMist: Insomnia
    • 14.155.3. ArTiMist: Malayria
    • 14.155.4. SUD-001: Migraine
    • 14.155.5. SUD-002: Nausea
    • 14.155.6. SUD-003: Erectile Dysfunction
    • 14.155.7. SUD-004: Pulmonary Arterial Hypertension
    • 14.155.8. SUD-005: Anxiety
  • 14.156. Supratek Pharma Inc.
    • 14.156.1. Biotransport Technology
    • 14.156.2. CombiForm Toolbox
    • 14.156.3. Product Pipeline
  • 14.157. Taiwan Liposome Co. Ltd.
    • 14.157.1. Technology
      • 14.157.1.1. Nano-Emulsion
      • 14.157.1.2. Polymeric Mycelle
      • 14.157.1.3. NanoX
      • 14.157.1.4. Immunoliposome
      • 14.157.1.5. BioSeizer
    • 14.157.2. Pipeline
      • 14.157.2.1. Doxisome
      • 14.157.2.2. Lipo-Dox
      • 14.157.2.3. Lipotecan
      • 14.157.2.4. TLC178
      • 14.157.2.5. AmBiL
      • 14.157.2.6. ProFlow
      • 14.157.2.7. ProDex
      • 14.157.2.8. TLC599
  • 14.158. TheraSource LLC
    • 14.158.1. rhMFG-E8
    • 14.158.2. Ghrelin
    • 14.158.3. AM/AMBP-1
  • 14.159. Transgene SA
  • 14.160. Valeant Pharmaceuticals International Inc.
    • 14.160.1. Efudex
  • 14.161. Vect-Horus S.A.S.
    • 14.161.1. Technology
    • 14.161.2. Vect-Horus' Scientific Collaboration with Servier
    • 14.161.3. Vect-Horus' Scientific Collaboration with Servier
  • 14.162. Vectura Group plc
    • 14.162.1. PowderHale
    • 14.162.2. ParticleMax
    • 14.162.3. GyroHaler
    • 14.162.4. Akita Jet
    • 14.162.5. Akita Apixneb
    • 14.162.6. Fox
  • 14.163. Vical Inc.
    • 14.163.1. Poloxamer Delivery System
    • 14.163.2. Vaxfectin Adjuvant
  • 14.164. Voyager Therapeutics Inc.
  • 14.165. WAVE Life Sciences Pvt. Ltd.
    • 14.165.1. Platform
  • 14.166. Xel Pharmaceuticals
    • 14.166.1. Xel's Proprietary Drug Delivery Technologies
    • 14.166.2. Transdermal Delivery System
    • 14.166.3. Topical Delivery System
    • 14.166.4. Implant Delivery Systems
    • 14.166.5. Oral Controlled Release
    • 14.166.6. Effervescent Tablet/Lozenge
    • 14.166.7. Cold Water Extraction
  • 14.167. Xenetic Biosciences
    • 14.167.1. Technologies
      • 14.167.1.1. PolyXen
      • 14.167.1.2. OncoHist
  • 14.168. Xigen SA
    • 14.168.1. Technology
  • 14.169. Zealand Pharma AS
  • 14.170. Zozano Pharma Corp.
    • 14.170.1. ZP-PTH
    • 14.170.2. Zozano's Product Pipeline

INDEX OF FIGURES

  • Figure 1.1: Summary of Targeted Drug Delivery Market, Through 2021
  • Figure 2.1: Conventional and Ideal Drug Release Profiles
  • Figure 2.2: Schematic Representation of Active Targeting
  • Figure 2.3: Diagrammatic Representation of Passive Targeting
  • Figure 3.1: Internalization of Nanomedicine
  • Figure 3.2: Conceptual Visualization of a Future Multifunctional Nanomedicine
  • Figure 4.1: Classication and Type of Liposomes
  • Figure 4.2: Diagrammatic Representation of a Liposome
  • Figure 4.3: Drug Loading Efficiency of Liposomes
  • Figure 4.4: Intracellular Delivery by pH-Sensitive and Plain Liposomes
  • Figure 4.5: Schematic Diagram of a Stealth Liposome
  • Figure 4.6: Schematic of Tumor Targeting Multifunctional Liposome
  • Figure 4.7: Stimuli Sensitive Multifunctional Targeted Liposome with Low pH Degradable Bonds
  • Figure 5.1: Delivery of Drugs by Polymers
  • Figure 6.1: Schematic Diagram Showing Micelle Formation
  • Figure 6.2: Drug-Loaded Polymeric Micelles with Various Targeting Functions
  • Figure 6.3: A Hypothetical Polymeric Micelle
  • Figure 7.1: Three-Dimensional Structure of Dendrimers
  • Figure 7.2: Dendrimers as Multifunctional Nanoplatforms
  • Figure 8.1: Mechanism of Antimicrobial Activity of Carbon Nanotubes
  • Figure 8.2: Trimetalic Nitride Endoherdral Metallofullerene and Empty Cage Fullerene C70
  • Figure 8.3: Schematic Illustration of Preparation, Drug Loading and Drug Delivery by GO
  • Figure 8.4 AuNPs with Conjugated Drug
  • Figure 8.5: Shaped of Gold Nanoparticles
  • Figure 8.6: Drug Carrying Ability of Silica Nanoparticles
  • Figure 8.7: A Typical Design of a Magnetic Nanoparticle
  • Figure 8.8: Shematic Representation of Magnetic Nanoparticles with Surface Modifications
  • Figure 8.9: Conceptual Representation of MNP Tumor Targeting
  • Figure 9.1: Schematic Representation of Dendritic Cells Expressing a Number of Different Cell Surface Receptors which are Targets for Antigen Targeting Therapies
  • Figure 9.2: Therapeutic Sites and Targets Accessible for RBC-Delivered Drugs
  • Figure 9.3: Procedure of Encapsulating Bacterial Ghost with Drugs
  • Figure 10.1: Different Possible Treatment Options of Cancer Using Peptides
  • Figure 10.2: Schematic of Peptide Receptor Radionuclide Therapy (PRRT)
  • Figure 10.3: Mechanism of Action of Peptide-Based Cancer Vaccines
  • Figure 10.4: Schematic Diagram of Aptamer Binding to its Target
  • Figure 10.5: Schematic Diagram of Nanobot for Targeted Drug Delivery
  • Figure 11.1: Tumor-Associated Antigens (TAA)
  • Figure 11.2: mAbs binding to Cancer Cells
  • Figure 11.3: Binding of Naked mAbs to the Antigens on Cancer Cells
  • Figure 11.4: Schematic Representation of Conjugated mAb
  • Figure 11.5: Binding of Radiolabeled mAbs to the Cancer Cells
  • Figure 11.6: A Bispecific mAb
  • Figure 11.7: Annual U.S./E.U. Approvals of mAbs as of 2015
  • Figure 11.8: Schematic Illustration of Formation of Spherical Micelle and Drug Encapsulation
  • Figure 12.1: Microchip Developed by Microchip Biotech
  • Figure 13.1: Application of Nanotechnology in Healthcare
  • Figure 13.2: Types of Nanomedicine Companies
  • Figure 13.3: Global Market for Nanomedicines by Geography, Through 2021
  • Figure 13.4: Global Market for Nanomedicines by Major Therapeutic Areas, Through 2021
  • Figure 13.5: Global Targeted Drug Delivery Market, Through 2021
  • Figure 13.6: Global Market for mAbs by Geography
  • Figure 13.7: Global Market for Humira, Remicade and Avastin, Throug 2021
  • Figure 13.8: Global Market for Rituxan, Soliris and Herceptin, Through 2021
  • Figure 13.9: Global Market for Kadcyla, Perjeta and Lucentis, Through 2021
  • Figure 13.10: Global Market for Xgeva/Prolia, Stelara and Tysarbi, Through 2021
  • Figure 13.11: Market for Nano-Based Targeted Drug Delivery Systems by Type, Through 2021
  • Figure 13.12: Global Market for Novel Ocular Drug Formulations and Implants, Through 2021
  • Figure 13.13: Global Market for Drug Eluting Stents by Geography, Through 2021
  • Figure 13.14: Global Market for Pulmonary Drug Delivery Technologies, Through 2021
  • Figure 14.1: Conventional and Heavy Chain Antibodies
  • Figure 14.2: Restoration of P53 Activity by Stapled Peptide Dual Inhibitor
  • Figure 14.3: Andros' Topical Delivery System
  • Figure 14.4: Andros' Gene Delivery System
  • Figure 14.5: Buccal and Oral Delivery of Peptides by Means of ArisCrown
  • Figure 14.6: BBB Therapeutics' G-Technology
  • Figure 14.7: Components of Accurins
  • Figure 14.8: Celsion's LTLD Technology
  • Figure 14.9: Mechanism of Action of Cerulean's NDCs
  • Figure 14.10: Mechanism of Action of EDV Nanocells
  • Figure 14.11: EryDel's Technology of Encapsulating Drugs into Erythrocytes
  • Figure 14.12: ERY-ASP's Mode of Action
  • Figure 14.13: Biochronomer Technology
  • Figure 14.14: IVECT Method of Targeted Drug Delivery
  • Figure 14.15: Improved Absorption Enabled by Lip'ral Technology
  • Figure 14.16: Nanocarrier's Platform Technology
  • Figure 14.17: Diagrammatic Description of NanoOncology's Technology
  • Figure 14.18: Neos Therapeutics' Ion Exchange Process
  • Figure 14.19: Mechanism of Action of Betalutin
  • Figure 14.20: Diagrammatic Representation of PGC
  • Figure 14.21: PolyActiva's Drug Polymer Conjugate
  • Figure 14.22: Interaction between Phosphorothioated NAPs and Amphipathic Protein Targets
  • Figure 14.23: The Making of Pendent POZ
  • Figure 14.24: The Making of Pendent POZ-Therapeutics
  • Figure 14.25: Diagrammatic Structure of Nano-Emulsion
  • Figure 14.26: Diagrammatic Structure of Polymeric Micelle
  • Figure 14.27: Diagramatic Representation of Drug Loading in NanoX
  • Figure 14.28: Diagrammatic Representation of the Specificity of Immunoliposomes
  • Figure 14.29: Xigen's ICPT Technology

INDEX OF TABLES

  • Table 1.1: Summary of Targeted Drug Delivery Market, Through 2021
  • Table 2.1: A Comparison of Release Obtained from Various Particulate Delivery Systems
  • Table 2.2: Advantages and Disadvantages of Targeted Drug Delivery
  • Table 2.3: Examples of Actively Targeted Micelles
  • Table 2.4: Examples of Passively Targeted Therapeutic Preparations of Polymeric Micelle
  • Table 2.5: Polymeric Nanoparticles Developed for Passive Delivery of Drugs for Cancer
  • Table 3.1: Advantages of Nanoparticles in Drug Delivery
  • Table 3.2: Ideal Drug Delivery Characteristics of Nanodrugs
  • Table 3.3: Sizes of Some Nanoconstructs used in Therapeutics and Diagnostics
  • Table 3.4: Examples of Nanomedicines Approved by One or More Regulatory Bodies
  • Table 3.5: Examples of Nanomedicines Approved by FDA
  • Table 3.6 Nanoparticle Cancer Therapeutics Undergoing Clinical Investigation
  • Table 3.7: Passive vs. Active Targeting
  • Table 3.8: Targets of Nanomedicines in Our Body
  • Table 3.9: Commonly Available Ligands in Drug Delivery
  • Table 3.10: Examples of Nanomedicine Applications
  • Table 3.11: Rationale for Nanotherapeutic Approach
  • Table 3.12: Commercially Available Nanotherapeutic Products for Oral Administration
  • Table 3.13: Commercially Available Nanotherapeutics for Parenteral Administration
  • Table 3.14: Examples of FDA-Approved Nanomedicines for Intravenous Route of Administration
  • Table 3.15: Examples of FDA-Approved Nanomedicines for Pulmonary Route of Administration
  • Table 3.16: Examples of FDA-Approved Nanomedicines for Subcutaneous, Intramuscular, Transdermal and Ocular Route of Administration
  • Table 3.17: Examples of Nano-Based Medical Devices and Diagnostics
  • Table 3.18: Different Types of Nanocarriers used in Formulating Nanomedicines
  • Table 3.19: Different Types of Synthesized Nanoforms used in Biomedical Field
  • Table 3.20: Use of Nanoparticles in Different Fields of Medicine
  • Table 3.21: Marketed Nanosystems for Cancer Treatment
  • Table 3.22: Synthetic Nanomaterials used in Tissue Engineering
  • Table 3.23: Natural Nanomaterials Used in Tissue Engineering
  • Table 3.24: Examples of NPs-Based Gene Delivery in Stem Cells
  • Table 3.25: Examples of Contrast Agents using Nanoparticles
  • Table 4.1: Advantages and Disadvantages of Liposomes as Targeted Systems
  • Table 4.2: Classification of liposomes on the Basis of Size
  • Table 4.3: Classification of Liposomes on the Basis of Method of Preparation
  • Table 4.4: Sizes of Liposomes
  • Table 4.5: New Generation of Liposomes and their Features
  • Table 4.6: Benefits of Drug Loads in Liposomes
  • Table 4.7: Representative List of Liposome-Based Drugs
  • Table 4.8: Liposome-Based Drugs for Cancer Therapy
  • Table 4.9: List of Liposomal Drugs in Clinical Trial
  • Table 4.10: Different Modifications in Liposomes for Improved Drug Delivery
  • Table 4.11: Approved Stealth Liposome Formulations
  • Table 4.12: Examples of Ligands used for Targeting of Liposomal Nanocarriers
  • Table 4.13: Examples of PEGylated Liposomes used for Active Targeting
  • Table 5.1: Advantages and Disadvantages of Polymer-Based Carriers
  • Table 5.2: Various Stimuli and Responsive Polymeric Materials
  • Table 5.3: Various Smart Polymeric Drug Delivery Systems
  • Table 5.4: Applications of Thermosensitive Polymers for Drug Delivery Systems
  • Table 5.5: Classification, Representative Thermosensitive Polymers and their Applications
  • Table 5.6: Various Applications of pH Sensitive Polymeric Drug Delivery Systems
  • Table 5.7: Applications of Bioresponsive Polymers
  • Table 5.8: Examples of Natural Polymer-Based Topical Delivery Systems
  • Table 5.9: Examples of Topical Delivery Systems Based on Synthetic Polymers
  • Table 5.10: Clinically Approved Polymeric Nanomedicine for Cancer Treatment
  • Table 5.11: Polymeric Nanoparticle-Based Therapeutics Undergoing Clinical Investigation
  • Table 6.1 Materials Used to Prepare Micelles and the Release Obtained from these Micelles
  • Table 6.2: Some Existing Approaches to Achieve Sustained Release from Micelle
  • Table 6.3 Examples of Stimuli-Responsive Micelles
  • Table 6.4: Passively-Targeted Therapeutic Formulations of Polymeric Micelle
  • Table 6.5: Examples of Actively Targeted Micelle
  • Table 6.6: Examples of Stimuli-Responsive Polymeric Micelles
  • Table 6.7: Examples of Multifunctional Drug-Loaded Micelles
  • Table 6.8: Examples of Multifunctional siRNA-Loaded Micelles
  • Table 6.9: Representative List of Drug-Loaded Polymeric Micelle-Based Products
  • Table 7.3: List of Commercially Available Dendrimers and Dendrimer-Based Products
  • Table 7.4: Therapeutic Moities Studied using Dendrimers
  • Table 7.5: Types of Thermosensitive Dendrimers
  • Table 8.1: Advantages and Disadvantages of Inorganic Nanoparticles
  • Table 8.2: Carbon-Based Nanoparticles as Antimicrobial Agents
  • Table 8.3: Comparison between MWCNT and SWCNT
  • Table 8.4: Applications of Nanotubes as Artificial Implants
  • Table 8.5: Examples of Carbon Nanotubes used for the Detection of Cancer Biomarkers
  • Table 8.6: Examples of Drugs and Nucleic acids Delivered by Carbon Nanotubes
  • Table 8.7: Summary of Biomedical Applications of Fullerenes
  • Table 8.8: Drug and Gene Delivery Applications of GO-Based Vehicles
  • Table 8.9: Imaging Applications of Gold Nanoparticles
  • Table 8.10: Drug Delivery Applications of Gold Nanoparticles
  • Table 8.11: Diagnostic Applications of Gold Nanoparticles
  • Table 8.12: Types of Silica Nanoparticles with their Internal Structure and Pore Diameter
  • Table 8.13: Common Chemical Constituents used in the Preparation of Silica Nanoparticles
  • Table 8.14: Types of Drugs Delivered through Silica Nanoparticles
  • Table 8.15: Advantages and Disadvantages of Magnetic Particles
  • Table 8.16: Magnetic Nanoparticles used in Biomedical Applications
  • Table 8.17: Examples of Coating Materials of Magnetic Nanoparticles
  • Table 8.18: Examples of Organic Linkers and their Applications in Magnetic Nanoparticles
  • Table 8.19: Commercially Available Magnetic Nanoparticles (Approved or in Clinical Trials)
  • Table 8.20: Clinical Trials Evaluating the Utility of Magnetic Nanoparticles as Diagnostics
  • Table 8.21: FDA/EMEA-Approved Magnetic Nanoparticle-Based Contrast Agents
  • Table 9.1: Advantages and Disadvantages of Cell-Based Systems
  • Table 9.2: Comparison of RBCs with other Drug Delivery Systems
  • Table 9.3: Examples of Therapeutic Enzymes Encapsulated in Carrier RBCs
  • Table 9.4: Clinical and Experimental Therapies using MSCs for Neural-Related Diseases
  • Table 10.1: Advantages and Disadvantages of Nucleic Acid/Peptide Carriers
  • Table 10.2: LHRH Agonists and New Generation Agonists Available in the Market
  • Table 10.3: Peptide Receptors having Potential in Cancer Therapy
  • Table 10.4: Types and Examples of Cell-Penetrating Peptides
  • Table 10.5: Peptides Applied in Cancer Diagnosis
  • Table 10.6: Examples of Peptides Applied in Treating Cancer
  • Table 10.7: Peptide-Based Vaccines in Development
  • Table 10.8: The Lone Approved Aptamer and other Aptamers in Development
  • Table 11.1: Current Targeted Drug Delivery Technologies for Cancer
  • Table 11.2: Categories and Examples of Tumor Antigens
  • Table 11.3: Examples of FDA-Approved Targeted Cancer Therapies
  • Table 11.4: Selected Cancer Therapies in Late Stage Development
  • Table 11.5: A Representative List of Naked mAbs
  • Table 11.6: Representative List of Conjugated mAbs
  • Table 11.7: Approved Antibody ARCs and ADCs
  • Table 10.8: Representative List of Bispecific mAbs (bsAbs)
  • Table 11.9: mAbs by Indication Area
  • Table 11.10: Late Stage mAb Biosimilar Development Activity
  • Table 11.11: Number of Biosimilars of Monoclonal Antibodies in Development
  • Table 11.12: Ocular Applications of Dendrimer Drug Delivery Systems
  • Table 11.13: Applications of Liposomes for Ocular Diseases
  • Table 11.14: List of Micellar Formulation of Ocular Drugs for Ocular Drug Delivery
  • Table 11.15: Viral and Non-Viral Systems for Ocular Delivery of Genes
  • Table 11.16: Different Types of Drug Delivery Methods for CNS Protection
  • Table 11.17: Drug Delivery Approaches and Drug Molecules for Brain
  • Table 11.18: Examples of Nanoparticles (NPs) used for Delivery of Drugs across BBB
  • Table 11.19: Examples of Clinically-Approved NPs Therapeutics for CNS Disorders
  • Table 11.20: Examples of Nanoparticle-Based Therapeutics for CNS in Clinical Trials
  • Table 11.21: Examples of Drugs Delivered through PAMAM Dendrimers for CNS
  • Table 11.22: Liposomes for Antimicrobial Drug Delivery
  • Table 11.23: Polymeric Nanoparticles for Antimicrobial Drug Delivery
  • Table 11.24: Solid Lipid Nanoparticles for Antimicrobial Drug Delivery
  • Table 11.25: Dendrimers for Antimicrobial Drug Delivery
  • Table 11.26: Examples of Contrast-Enhancing Nanoparticles for Cardiovascular Imaging
  • Table 11.27 Therapeutic and Theranostic Nanoparticles for CVD
  • Table 11.28: Nano-Based In vivo CVD Sensors
  • Table 11.29: Examples of Drugs used for Pulmonary Delivery using Colloidal Carrier Self-Assembling Systems
  • Table 11.30: Examples of Polymers for Colloidal Pulmonary Drug Delivery Systems
  • Table 11.31: Examples of Nebulizers with Novel Technologies
  • Table 11.32: Novel Dry Powder Inhalers Launched in the Past Decade
  • Table 11.33: Different API Molecules Incorporated into Different Nanoparticle Systems for Pulmonary Application
  • Table 11.34: Various Nano-Based Cosmeceutical Products in the Market
  • Table 12.1: Examples of Sustained Release Delivery Systems Studied in Glaucoma-Induced Preclinical Models
  • Table 12.2: Examples of Sustained Release Delivery Systems for Glaucoma that are Under Clinical Development
  • Table 12.3: Examples of FDA-Approved Ocular Drug Delivery Implants
  • Table 12.4: Delivery Systems Suitable for Sustained Trans-Scleral Drug Delivery for Retinal Disorders
  • Table 12.5: Examples of Drug Eluting Stents Available in the Market
  • Table 12.6: An Additional List of Polymer-Coated Stents
  • Table 13.1: Global Nanomedicines Market, Through 2021
  • Table 13.2: Global Nanomedicines Market by Therapeutic Area, Through 2021
  • Table 13.3: Global Targeted Drug Delivery Market, Through 2021
  • Table 13.4 Global Market for mAbs by Geography
  • Table 13.5: Global Market for Top Selling mAbs by Company, Class and Revenue Through 2021
  • Table 13.6: Global Market for Nano-Based Targeted Drug Delivery Market by Type, Through 2021
  • Table 13.7 Nanoparticles used in the Formulation of Ocular Drugs
  • Table 13.8: Liposomes used in the Formulation of Ocular Drugs
  • Table 13.9: Dendrimers Investigated for Ocular Drug Delivery
  • Table 13.10: Global Market for Ocular Drug Delivery, Through 2012
  • Table 13.11: Global Market for Ocular Drug Delivery by Geography, Through 2012
  • Table 13.12: Global Market for Drug Eluting Stents, Through 2021
  • Table 13.13: Global Market for Pulmonary Drug Delivery Technologies, Through 2021
  • Table 13.14: Global Market for Pulmonary Drug Delivery Technologies by Geography, Through 2021
  • Table 13.15: Hydrogel Systems with Polymers Examples for Oral Drug Delivery
  • Table 13.16: Examples of PEGylated Nanocarriers Studied in Rodent Models
  • Table 13.17: Cyclodextrins for Oral Drug Delivery
  • Table 13.18: Drugs Tested with Cyclodextrins for Rectal Delivery
  • Table 13.19: Drugs Tested with Cyclodextrins for Nasal Delivery
  • Table 13.20: Drugs Tested with Cyclodextrins for Transdermal Delivery
  • Table 13.21: Drugs Tested with Cyclodextrins for Ocular Drug Delivery
  • Table 13.22: Drugs Tested with Cyclodextrins for Controlled Drug Delivery
  • Table 14.1: Ablynx's Clinical Programs
  • Table 14.2: Aciont's Product Pipeline
  • Table 14.3: Alchemia's Product Pipeline
  • Table 14.4: Alkermes' Product Pipeline
  • Table 14.5: Alnylam's Product Pipeline
  • Table 14.6: AmpliPhi's Product Pipeline
  • Table 14.7: Angiochem's Product Pipeline
  • Table 14.8: AGTC's Product Pipeline
  • Table 14.9: Aradigm's Product Pipeline
  • Table 14.10: Armagen's Lysogen Storage Disorder Pipeline
  • Table 14.11: Armagen's Neurodegenerative Pipeline
  • Table 14.12: Arrowhead's Pipeline
  • Table 14.13: Asklepios' Product Pipeline
  • Table 14.14: Audentes' Product Pipeline
  • Table 14.15: Avalanche's Product Pipeline
  • Table 14.16: BBB's Product Pipeline
  • Table 14.17: BIND Therapeutics' Intellectual Property
  • Table 14.18: Camurus' Product Pipeline
  • Table 14.19: Celsion's Pipeline
  • Table 14.20: Cerulean's Product Pipeline
  • Table 14.21: Copernicus' Product Pipeline
  • Table 14.22: CureVac's Product Pipeline
  • Table 14.23: Discovery Lab's Product Pipeline
  • Table 14.24: DURECT's Product Pipeline
  • Table 14.25: Ensyce's Product Pipeline
  • Table 14.26: Overview of EryTech's Development Projects
  • Table 14.27: EryTech's Financial Data
  • Table 14.28: Esperance's Product Pipeline
  • Table 14.29: Exicure's Product Pipeline
  • Table 14.30 GenVec's Product Pipeline
  • Table 14.31: Glide's Development Programs
  • Table 14.32: Heron's Product Pipeline
  • Table 14.33: iCeutica's Pain & Inflammation Product Pipeline
  • Table 14.34: iCeutica's Oncology Drug Pipeline
  • Table 14.35: iCeutica's Respiratory Drug Pipeline
  • Table 14.36: iCeutica's Migraine Drug Pipeline
  • Table 14.37: ImmusanT's Product Pipeline
  • Table 14.38: InDex's Product Pipeline
  • Table 14.39: Immune Design's Product Pipeline
  • Table 14.40: Immunocore's Product Pipeline
  • Table 14.41: Inovio's Product Pipeline
  • Table 14.42: Insight Vision's Product Pipeline
  • Table 14.43: Insmed's Product Pipeline
  • Table 14.44: Intezyne's Pipeline
  • Table 14.45: LipimetiX's Product Pipeline
  • Table 14.46: LiPlasome's Pipeline
  • Table 14.47: Lipocine's Product Pipeline
  • Table 14.48: Lipotek's R&D Program
  • Table 14.49: Madison's Product Pipeline
  • Table 14.50: Mersana's Product Pipeline
  • Table 14.51: Milo's Product Pipeline
  • Table 14.52: miRagen's Product Pipeline
  • Table 14.53: MultiVir's Product Pipeline
  • Table 14.54: Nanocarrier's Product Pipeline
  • Table 14.55: Nanotherapeutics' Product Pipeline
  • Table 14.56: NanoViricides' Product Pipeline
  • Table 14.57: Nektar's Approved Products
  • Table 14.58: Nektar's Product Pipeline
  • Table 14.59: Neos Therapeutics' Product Candidates
  • Table 14.60: NOD's Product Pipeline
  • Table 14.61: Oxford Biomedica's Product Pipeline
  • Table 14.62: PDS' Product Pipeline
  • Table 14.63: PharmaIN's Product Pipeline
  • Table 14.64: PhaseRx's Product Pipeline
  • Table 14.65: pSivida's Product Pipeline
  • Table 14.66: Pulmatrix's Product Pipeline
  • Table 14.67: Quark's Pipeline of Products
  • Table 14.68: RaNA's Product Pipeline
  • Table 14.69: RegeneRx's Product Pipeline
  • Table 14.70: Regenxbio's Product Pipeline
  • Table 14.71: Renova Therapeutics' Product Pipeline
  • Table 14.72: Replicor's Phase II Proof of Concept Clinical Study Pipeline
  • Table 14.73: Replicor's Regulatory Pipeline
  • Table 14.74: RJS Biologics' Product Pipeline
  • Table 14.75: Sarfez's Product Pipeline
  • Table 14.76: Savara's Product Pipeline
  • Table 13.77: Serin'a Pipeline
  • Table 14.78: Silence's Product Pipeline
  • Table:14.79: Silenseed's Product Pipeline
  • Table 14.80: Sylentis' Product Pipeline
  • Table 14.81: Spark's Product Pipeline
  • Table 14.82: Transgene's Product Pipeline
  • Table 14.83: Vect-Horus' Product Pipeline
  • Table 14.84: Vectura's Pipeline Assets
  • Table 14.85: Vicas' Product Pipeline
  • Table 14.86: Voyager's Product Pipeline
  • Table 14.87: WAVE's Product Pipeline
  • Table 14.88: Xel's Pipeline
  • Table 14.89: Xenetic Biosciences' Product Pipeline
  • Table 14.90: Xigen's Product Pipeline
  • Table 14.91: Zealand Pharma's Product Pipeline
  • Table 14.92: Zozano's Product Pipeline
Back to Top